Halozyme Pulls €2B Bid After Evotec Fails To Engage In Talks
California-based biopharmaceutical company Halozyme Therapeutics Inc. on Friday said it has withdrawn its €2 billion ($2.1 billion) proposal to acquire European biotechnology company Evotec SE, saying that Evotec's board made it...To view the full article, register now.
Already a subscriber? Click here to view full article